argenx Upgraded to Buy on VYVGART Growth, Label Expansion

Argenx (ARGX) is getting an upgrade to BUY from HOLD. Three things drove the call: the company keeps delivering on commercial execution for VYVGART, it has a clear path to label expansion, and the balance sheet is de-risked enough to fund the pipeline without a dilutive raise. The analyst behind the call now sees more upside than downside.

VYVGART, the company's FcRn blocker for generalized myasthenia gravis (gMG), has been the core revenue driver. Launch trends in the U.S. have held steady, with new patient starts continuing at a pace that supports the current revenue run rate. The analyst noted that the trajectory of VYVGART sales, combined with expanding approval in additional indications, is what makes the growth cycle sustainable.

The label expansion piece is central to the upgrade. Argenx has several shots on goal: subcutaneous VYVGART formulations, CIDP (chronic inflammatory demyelinating polyneuropathy), and other autoimmune indications. A positive readout in any of these could meaningfully broaden the addressable market beyond gMG. The analyst cited the CIDP data as a potential catalyst that would add billions in peak sales if approved.

Balance sheet risk is lower now than it was a year ago. Argenx ended the most recent quarter with roughly $1.7 billion in cash and equivalents and no debt. The company is generating enough revenue from VYVGART to cover operating expenses without burning through the cash pile at the rate it did during the development phase. That removes the risk of a dilutive secondary offering, which had been a concern earlier, the analyst said.

The bear case on argenx has centered on competition in the FcRn space. Johnson & Johnson and UCB both have approved drugs targeting the same mechanism. Argenx countered with real-world data showing VYVGART maintains a strong position on efficacy and safety. The analyst acknowledged competition but said the market is large enough for multiple players. The bigger risk, in the view behind the upgrade, is execution on pipeline data and label expansion, not near-term revenue erosion.

Argenx trades at roughly 6x the peak sales estimate baked into the current consensus. That multiple leaves room for upside if any of the pipeline catalysts hit, the analyst said. The stock has rallied about 25% over the past six months but still sits 20% below the 52-week high set last summer.

For a broader comparison of biotech investment cases, see the gold profile for risk-off positioning and commodities analysis for alternative sector exposure.

The next major catalyst is the CIDP Phase 3 readout, expected in the first half of 2025. A positive result would trigger a wave of analyst revisions, the analyst wrote. The upgrade is in place ahead of that data.